Company intelligence / Profile preview

BioCopy

Basel, Basel-Stadt, Switzerland

Ownership: Private
Employees: ~10
Development stage: Other

Overview

BioCopy has five preclinical programs: three in solid tumors (bladder, ovarian, lung cancers) starting 2024/2025 and two in blood cancer (acute myeloid leukemia) beginning in 2025/2026. Aim is to provide drug candidates for clinical evaluation within 3-4 years.

Therapeutic areas: OncologyHematologyImmunology
Modalities: Monoclonal antibodyBispecific monoclonal antibodyMultispecific biotherapeutic
Industry: Biotech

Drug pipeline

1 asset

BioCopy Program 5

Preclinical

Partnerships

Genedata (software/data backbone)

Beyond the preview

Go deeper on BioCopy.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BioCopy.

Explore the full profile